Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy
BOSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with ...
What are the risks of trial setbacks or adverse events in this early‑stage study that could negatively impact the stock?
How might the Phase 2a enrollment update influence analyst coverage, consensus estimates, and target price revisions for TLSA?
Are there any partnership or licensing agreements in place that could be triggered by positive trial data, potentially affecting liquidity or dilution?
10 days ago